Oxyphencyclimine

Summary

Oxyphencyclimine (CHEMBL1495) is an approved small molecule (ATC A03AA01); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A03AA01
• Indications: 1 condition
• Chemistry: 344.4 Da · C20H28N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1495
Name	Oxyphencyclimine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4642
ATC	A03AA01
Molecular formula	C20H28N2O3
Molecular weight	344.4
InChIKey	DUDKAZCAISNGQN-UHFFFAOYSA-N

SMILES: CN1CCCN=C1COC(=O)C(C2CCCCC2)(C3=CC=CC=C3)O

IUPAC name: (1-methyl-5,6-dihydro-4H-pyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate

Also known as: Oxifenciclimina, Oxyphencyclimine, OXYPHENCYCLIMINE, OXYPHENCYCLIMINE HYDROCHLORIDE, oxyphencyclimine

Parent form; salt/anhydrous children: CHEMBL1200891

Patent coverage: 501 distinct patent families (1,670 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Equilibrative nucleoside transporter 1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Histamine H1 receptor, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM1	7.72	AC50	19	nM	CHEMBL_ACT_25135848
CHRM2	7.58	AC50	26.3	nM	CHEMBL_ACT_25195357
CHRM2	7.16	AC50	70	nM	CHEMBL_ACT_25214103
HRH1	6	AC50	990	nM	CHEMBL_ACT_25212902
KCNH2	5.42	AC50	3775	nM	CHEMBL_ACT_25118415

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).